Incretin Atlas › Trials › TRANSCEND-T2D-1 (T2D monotherapy)
TRANSCEND-T2D-1 (T2D monotherapy)
Retatrutide · t2d
Design
- Molecule(s)
- Retatrutide
- Population
- t2d
- Official title
- Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
- Sponsor
- Eli Lilly and Company
- Phase
- 3
- Registry status
- completed · 2024-04 → 2026-01
- Participants
- 537
- Duration
- 40 weeks
- Registry
- NCT06354660
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| retatrutide 12 mg | t2d | 40 | 537 | −16.8 % vs −2.5 % Δ −14.3 pp | −16.8 % vs −2.5 % Δ −14.3 pp | −1.9 vs −0.8 | 5.1 vs 0.0 | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- retatrutide 12 mg: Weight −11.5 % (4 mg) and −15.5 % (9 mg); HbA1c −1.7 to −2.0 % vs −0.8 %. The values shown are the 12 mg arm.
Verbatim quotes from the source (3)
- retatrutide 12 mg · weight_eff · Results
The estimated mean percent change from BL in BW was -11.5% with 4 mg, -15.5% with 9 mg, -16.8% with 12 mg retatrutide vs -2.5% with placebo (all p<0.001).
- retatrutide 12 mg · ae_dc · Results
Discontinuation due to AEs occurred in 2.2% (4 mg), 4.5% (9 mg), and 5.1% (12 mg) participants treated with retatrutide, versus 0% with placebo.
- retatrutide 12 mg · hba1c · Results
The estimated mean change from BL in HbA1c was -1.7% (-18.5 mmol/mol) with 4 mg, -2.0% (-22.0 mmol/mol) with 9 mg, and -1.9% (-21.0 mmol/mol) with 12 mg retatrutide
Primary sources
- Harpreet S. Bajaj et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist in patients with type 2 diabetes treated with diet and exercise alone (TRANSCEND-T2D-1). Abstract 15. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: OP 03 GLP-1 and friends: new clinical insights]
- ClinicalTrials.gov NCT06354660
How to cite this page
Medical Adviser's Group. Incretin Atlas: TRANSCEND-T2D-1 (T2D monotherapy). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/transcend-t2d-1/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.